Dyadic: Dyadic to Present at World Vaccine Congress | Washington

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.World Vaccine Congress | Washington, D.C.April 22-24, 2025Presentation: Wednesday, April 23, 2025 | 12:40 PM-1:10 PMTrack: Influenza & Respiratory | Room 202ATopic: C1 Platform: The Urgent Need for Smarter Biomanufacturing - A Call to Action on Avian Influenza (H5N1) & Future PandemicsDuring the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic's proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production."We are excited to share the latest pre-clinical data from multiple studies demonstrating that Dyadic's proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies," said Mr. Emalfarb. "Leveraging our C1 platform, we aim to enable rapid, cost-effective production of antigens, reagents and ...Full story available on Benzinga.com